SARS-CoV-2 and the dopaminergic system
Submitted by emily.kilby on Thu, 02/11/2021 - 10:02

DOWNLOAD PDF

SARS-CoV-2 and the dopaminergic system
 

Patrik Brundin MD, PhD
 

Center for Parkinson’s Disease Research, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave., N.E., Grand Rapids, MI, USA. Email: Patrik.Brundin@vai.org

 

A significant portion of COVID-19 survivors exhibit neurological deficits, and upon close examination also display pathological changes in the nervous system. Recent reports describe three patients hospitalized with severe COVID-19 who developed clinical parkinsonism, in isolation or with other neurological deficits, within 2-5 weeks of contracting SARS-CoV-2 [1-3]. In all three cases, brain imaging revealed reduced function of the nigrostriatal dopaminergic system. Two received dopaminergic drugs and experienced clinical benefit [2,3], while the third patient spontaneously recovered from the parkinsonism [1].  These cases do not definitely prove a causal relationship between SARS-CoV-2 infection and acute parkinsonism, but the rapid onset of severe motor symptoms shortly after the viral infection is suggestive. None of the patients had a family history of Parkinson’s disease (PD), or showed signs of prodromal PD. One patient underwent genetic testing and did not carry any of the major PD risk variants [2].

 

What might be the underlying mechanisms of the acute onset of parkinsonism following COVID-19? While the initial trigger(s) of sporadic PD are not known [4], bacterial and viral infections have been implicated [5, 6]. There are three potential mechanisms for the rapid development of parkinsonism that may occur either alone or in concert [7]. First, vascular insults occur in multiple organs, including the brain, in severe COVID-19 [8].  One neuropathology study emphasized microvascular lesions in different brain regions including the substantia nigra [9] and microglial activation as well as invading cytotoxic T cells have also been observed in the brainstem [10]. Second, the systemic inflammation that occurs in severe COVID-19 could possibly trigger neuroinflammation and demise of nigral dopamine neurons. Midbrain dopamine neurons are believed to be particularly susceptible to systemic inflammation. In COVID-19, the level of IL-6 is elevated, and the kynurenine pathway is perturbed [11], changes that both are relevant to PD [12]. Third, SARS-CoV-2 RNA has been detected in brain tissue, indicating that it is neurotropic. The neuropathology and clinical features of prodromal PD suggest that the disease process in PD might be triggered in the olfactory system (causing hyposmia) or in enteric nerves (leading to constipation) and then propagates to, for example, the substantia nigra [4] . Strikingly, hyposmia (and dysguesia) are common in COVID-19, and SARS-CoV-2 can infect the olfactory epithelium [13], possibly using Neuropilin-1 receptors to gain entry to the cells [14]. Notably, in COVID-19 there are microvascular lesions specifically in the olfactory system and dorsal motor nucleus of the vagal nerve [9] that innervates the digestive and respiratory tracts which both are favored sites of attack of SARS-CoV-2. Midbrain dopamine neurons express high levels of the ACE2 receptor which is essential for SARS-CoV-2 entry [15]. Upregulation of neuronal alpha-synuclein can occur following invasion of other viruses [16, 17], and elevated alpha-synuclein is associated with Lewy body pathology. Thus, it is conceivable that people infected with SARS-CoV-2 might end up being predisposed to PD later in life. 
While the development of acute parkinsonism following COVID-19 is a rare event, the three case studies might tell us something fundamentally important about underlying disease mechanisms in sporadic PD, and they highlight the need to be vigilant of changes in the incidence of PD in the post-COVID-19 era.

 

Acknowledgements
P.B. is supported by funding from Van Andel Institute, NINDS and the Farmer Family Foundation on projects related to infections and Parkinson’s disease.

 

Declarations of interest
P.B. has received commercial support as a consultant from Axial Therapeutics, Calico Life Sciences, CuraSen, Fujifilm-Cellular Dynamics Inc, Idorsia, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Therapeutics and is on the steering committee of the NILO-PD trial. 

 


References

1.    Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 2020;95(15):e2109-18


2.    Cohen ME, Eichel R, Steiner-Birmanns B et al. A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol 2020;19(10):804-5


3.    Faber I, Brandão PRP, Menegatti F et al. Coronavirus disease 2019 and parkinsonism: a non‐post‐encephalitic case. Mov Disord 2020 Oct;35(10):1721-2


4.    Johnson ME, Stecher B, Labrie V et al.  Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis. Trends Neurosci 2019;42(4):13


5.    Tulisiak C, Mercado G, Peelaerts W et al.  Can infections trigger alpha-synucleinopathies? Progr Mol Biol Transl Sci 2019;168:299-322


6.    Smeyne RJ, Noyce AJ, Byrne M et al.  Infection and risk of Parkinson’s disease. J Parkinsons Dis 2020 Dec 22. doi: 10.3233/JPD-202279. Online ahead of print


7.    Brundin P, Nath A, Beckham JD.  Is COVID-19 a perfect storm for Parkinson’s disease? Trends Neurosci 2020 Dec;43(12):931-3


8.    Fabbri VP, Foschini MP, Lazzarotto T et al. Brain ischemic injury in COViD19 infected patients: a series of 10 post‐mortem cases. Brain Pathol 2020 Oct 1;e12901.doi: 10.1111/bpa.12901. Online ahead of print


9.    Lee M-H, Perl DP, Nair G et al. Microvascular injury in the brains of patients with Covid-19. New Engl J Med 2020;doi:10.1056/NEJMc2033369. Online ahead of print


10.    Matschke J, Lütgehetmann M, Hagel C et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020;19(11):919-29 


11.    Thomas T, Stefanoni D, Reisz JA et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 2020;5(14):e140327


12.    Heilman PL, Wang EW, Lewis MM et al.  Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson’s disease. Mov Disord 2020;35(11):2028-37


13.    Meinhardt J, Radke J, Dittmayer C et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2020 Nov 30; doi:10.1038/s41593-020-00758-5. Online ahead of print


14.    Cantuti-Castelvetri L, Ojha R, Pedro LD et al.  Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020;370:856-60

 
15.    Yang L, Han Y, Nilsson-Payant B et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 2020;27(1):125-36


16.    Beatman EL, Massey A, Shives KD et al.  Alpha-synuclein expression restricts RNA viral infections in the brain. J Virol 2015;90(6):2767-82


17.    Bantle CM, Phillips AT, Smeyne RJ et al.  Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. NPJ Parkinsons Dis 2019;5:20 

 

UK-APO-2100025
January 2021